GSK3B and gastric cancer: EGCG ((-)-Epigallocatechin-3-gallate) suppressed the proliferation and decreased the expression of p-β-catenin, p-GSK3β, and β-catenin target genes by inhibiting Wnt/β-catenin signaling in GC cells (42).